Company Encyclopedia
View More
name
ApicHope
300723.SZ
ApicHope Pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of pharmaceutical drugs in China. The company offers pediatric medicines, such as fuganlin and yiqi jianpi oral liquids, carboxymestrine oral solutions, and xiao’er kechuanling oral liquid products; and clindamycin palmitate hydrochloride dispersible tablets, acetylkitasamycin for suspension, qinxiangqingjie oral liquids, epinastine hydrochloride granules, clindamycin palmitate hydrochloride granules, clindamyxin hydrochloride for injection, clindamycin phosphate injection, ambroxol hydrochloride drops, montelukast sodium oral granules, oseltamivir phosphate capsules, and levocetirizine dihydrochloride oral drops. It also provides chronic disease drugs, including aciclovir for injection, hepatocyte growth-promoting factor for injection, pentoxifylline injection, kangshen and niaoqingshu granules, shenbo lotion, compound monoammonium glycyrrhizinate s and lansoprazole for injection, omeprazole sodium for injection, and other products.
3.165 T
300723.SZMarket value -Rank by Market Cap -/-

Financial Score

09/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking182/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-21.85%E
    • Profit Margin-41.93%E
    • Gross Margin61.64%A
  • Growth ScoreE
    • Revenue YoY-45.90%E
    • Net Profit YoY-24.92%D
    • Total Assets YoY-0.82%D
    • Net Assets YoY-19.38%E
  • Cash ScoreE
    • Cash Flow Margin-238.47%D
    • OCF YoY-45.90%E
  • Operating ScoreD
    • Turnover0.23D
  • Debt ScoreD
    • Gearing Ratio60.26%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ApicHope Pharmaceutical's Unit Gets Registration Certificate for Alzheimer's Treatment Drug: Shares Up 9%

    ApicHope Pharmaceutical's Unit Gets Registration Certificate for Alzheimer's Treatment Drug: Shares Up 9%

    marketscreener·
    SZ
    300723
    -1.47%
    marketscreener·
    SZ
    300723
    -1.47%

    ApicHope released its performance for the first three quarters, with a net loss attributable to the parent company of 136 million yuan

    According to the Zhitong Finance APP, ApicHope released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 814 million yuan, a year-on-year decrease of 34.35%. The net loss attributable to shareholders of the listed company was 136 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 179 million yuan. The basic loss per share was 0.3013 yuan

    Zhitong·
    SZ
    300723
    -1.47%
    Zhitong·
    SZ
    300723
    -1.47%

    ApicHope: The latest clinical results of the innovative drug deuterated benzbromarone for the treatment of gout stones were released at ACR 2025

    ApicHope announced on its official WeChat account that the latest clinical results of deuterated benzbromarone for the treatment of gout stones have been published at ACR 2025. The study shows that the drug is effective for both treatment-naive and refractory gout stone patients, significantly reducing uric acid levels and urate crystal burden, and improving the complete dissolution rate of gout stones, providing a more effective treatment option for patients with chronic gout stones

    Zhitong·
    SZ
    300723
    -1.47%
    Zhitong·
    SZ
    300723
    -1.47%

    ApicHope: Subsidiary's innovative drug APH03621 tablets approved for clinical trials

    ApicHope's wholly-owned subsidiary, Guangzhou ApicHope Pharmaceutical Co., Ltd., has received clinical trial approval from the National Medical Products Administration for its innovative drug APH03621 tablets, and clinical trials will be conducted soon. This drug is a novel oral, non-peptide small molecule gonadotropin-releasing hormone receptor antagonist aimed at treating endometriosis. Currently, there are no approved oral small molecule GnRH antagonists in the domestic market. This approval will have little impact on the company's short-term financial condition and operating performance

    Zhitong·
    SZ
    300723
    -1.47%
    Zhitong·
    SZ
    300723
    -1.47%

    ApicHope Pharmaceutical Unit Gets China Approval for Muscle Weakness Treatment

    ApicHope Pharmaceutical Unit Gets China Approval for Muscle Weakness Treatment

    marketscreener·
    SZ
    300723
    -1.47%
    marketscreener·
    SZ
    300723
    -1.47%
    © 2025 Longbridge｜Disclaimer